The arc traced in this series — from ancient Mesopotamian demonology to ICD-11 code 6C72 — is not a simple story of scientific progress. It is a more complex narrative: the gradual disentanglement of genuine clinical observation from moral regulation, the incremental development of epistemological standards adequate to behavioral phenomena, the emergence and partial resolution of competing theoretical frameworks, and the persistent tension between the imperative to help people who are suffering and the imperative to avoid pathologizing experiences whose primary character is cultural, moral, or simply human.
The biological substrate of CSBD remains incompletely characterized. Neuroimaging studies document reward-pathway overlap with substance use disorders, and the Parkinson’s dopamine agonist evidence provides pharmacological confirmation of dopaminergic involvement. But no neurobiological marker distinguishes CSBD from normative high drive, no validated biomarker exists, and the neurobiological evidence base is insufficient to adjudicate between the addiction and impulse-control frameworks. This is not a counsel of despair; it is an accurate description of where the science stands, and it does not impede effective clinical practice.
The psychological dimension is better documented and more immediately clinically actionable. Affect dysregulation is central — compulsive sexual behavior functions, for many patients, as a reliable and immediate method of managing dysphoric states. Cognitive permissive beliefs maintain the behavior between motivational cycles. Attachment insecurity is pervasive in clinical samples and shapes the relational terrain in which both the disorder and its treatment operate. These psychological mechanisms are addressable through existing evidence-based frameworks, even in the absence of disorder-specific treatment trials.
The social dimension is indispensable and historically underweighted in CSBD’s clinical literature. The meaning patients assign to their sexual behavior — shaped by religious tradition, cultural context, relational history, and the normative frameworks of their communities — is not merely relevant background information. It is often the primary clinical variable. The moral incongruence exclusion criterion is not a technicality; it is an acknowledgment that a substantial proportion of help-seeking behavior in this domain reflects values conflict rather than behavioral disorder, and that accurate diagnosis requires distinguishing between them.
Significant uncertainties remain. The nosological question — addiction versus impulse-control disorder — has not been resolved. Validated assessment instruments aligned to ICD-11 criteria do not yet exist. The treatment evidence base is borrowed and extrapolated. The demographic limitations of existing research create genuine uncertainty about applicability across populations. And the digital transformation of sexual behavior contexts has produced a clinical landscape that existing frameworks were not developed to address.
What is no longer uncertain is that a clinically significant and meaningfully impairing syndrome exists, that ICD-11 has provided a defensible diagnostic framework for it, and that the field now has the diagnostic anchor necessary to build the research infrastructure it previously lacked.
For the clinician engaging with this field, the appropriate posture is calibrated uncertainty: confident enough in the operational criteria and accumulated clinical wisdom to assess and treat patients presenting with genuine functional disorder; humble enough about the theoretical and empirical foundations to resist the certainty that the field’s more enthusiastic advocates have sometimes projected; and historically literate enough to recognize when clinical practice is inadvertently reproducing the errors of the past under new terminological clothing.
The patients who present with this condition — often after years of shame, secrecy, and failed attempts at self-management; often carrying layers of moral self-condemnation whose genealogy stretches back centuries; often uncertain whether their suffering constitutes a medical problem or a moral failing — deserve a rigorous assessment and a clinical posture that is neither dismissive nor credulous. The long encounter between medicine and human desire has produced, at last, a framework adequate to their experience. Using it well requires the kind of historical and conceptual literacy this series has attempted to provide.
The ICD-11 classification of CSBD under impulse-control disorders, rather than addictive disorders, should not be read as a settled ontological claim. It is a methodologically defensible nosological position reflecting the evidence available at the time of classification. Clinicians should communicate this to patients who ask whether CSBD is “really an addiction” — the honest answer is that the evidence remains insufficient to resolve that question, and that the diagnosis does not depend on resolving it. The demographic limitations of CSBD research are not merely academic limitations. They are clinical limitations. Clinicians treating female, LGBTQ+, and non-Western patients are applying knowledge generated in different populations. This warrants active attention to individual presentation, willingness to revise formulations that do not fit, and epistemic humility about prevalence and treatment response estimates. The most useful near-term research development for practicing clinicians would be an ICD-11-validated screening instrument that reliably separates functional CSBD from moral incongruence presentations. Until such an instrument exists, the clinical interview — not any available screening tool — is the gold standard for CSBD assessment.